Financial reports
10-K
2023 FY
Annual report
5 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
3 Mar 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
Current reports
8-K
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4 Apr 24
8-K
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
8 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation
9 Nov 23
8-K
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Departure of Directors or Certain Officers
7 Nov 23
8-K
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver MeetingĀ® 2023
11 Oct 23
8-K
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
11 Sep 23
8-K
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
3 Aug 23
Registration and prospectus
S-8
Registration of securities for employees
3 Aug 23
S-8
Registration of securities for employees
4 Aug 22
424B5
Prospectus supplement for primary offering
3 Mar 22
D
$15M in equity, sold $15M, 1 investor
30 Dec 21
S-3
Shelf registration
4 Nov 21
424B5
Prospectus supplement for primary offering
8 Oct 21
S-8
Registration of securities for employees
5 Aug 21
424B5
Prospectus supplement for primary offering
4 Mar 21
S-3
Shelf registration
28 Aug 20
424B5
Prospectus supplement for primary offering
7 Aug 20
Proxies
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
DEFA14A
Additional proxy soliciting materials
11 Apr 22
DEF 14A
Definitive proxy
11 Apr 22
DEFA14A
Additional proxy soliciting materials
8 Apr 21
DEF 14A
Definitive proxy
8 Apr 21
DEF 14A
Definitive proxy
24 Apr 20
DEF 14A
Definitive proxy
23 Apr 19
Other
EFFECT
Notice of effectiveness
19 Nov 21
CORRESP
Correspondence with SEC
16 Nov 21
UPLOAD
Letter from SEC
16 Nov 21
EFFECT
Notice of effectiveness
23 Oct 20
CORRESP
Correspondence with SEC
21 Oct 20
UPLOAD
Letter from SEC
3 Sep 20
CT ORDER
Confidential treatment order
1 Sep 20
CT ORDER
Confidential treatment order
23 Jul 20
EFFECT
Notice of effectiveness
13 Jan 20
CORRESP
Correspondence with SEC
8 Jan 20
Ownership
SC 13G/A
Whitefort Capital Management, LP
14 Feb 24
SC 13G/A
Two Seas Capital LP
14 Feb 24
SC 13G/A
BlackRock Inc.
12 Feb 24
4
J. Christopher Naftzger
5 Feb 24
4
Karen Sims
5 Feb 24
4
DAVID C HASTINGS
5 Feb 24
4
Michael J. Sofia
5 Feb 24
4
Michael J. McElhaugh
5 Feb 24
SC 13G
Two Seas Capital LP
21 Nov 23
SC 13G
Whitefort Capital Management, LP
11 Sep 23